123 related articles for article (PubMed ID: 27127393)
1. Incidence of metabolic syndrome in breast cancer survivors on adjuvant hormonal therapy.
Kate A; Kadambari D
J Pharmacol Pharmacother; 2016; 7(1):28-30. PubMed ID: 27127393
[No Abstract] [Full Text] [Related]
2. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
[TBL] [Abstract][Full Text] [Related]
3. Symptoms of hormonal therapy and social support: Is there a connection? Comparison of symptom severity, symptom interference and social support among breast cancer patients receiving and not receiving adjuvant hormonal treatment.
Ochayon L; Tunin R; Yoselis A; Kadmon I
Eur J Oncol Nurs; 2015 Jun; 19(3):260-7. PubMed ID: 25529935
[TBL] [Abstract][Full Text] [Related]
4. Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Bell R; Lewis J
Curr Med Res Opin; 2007 May; 23(5):1045-51. PubMed ID: 17519070
[TBL] [Abstract][Full Text] [Related]
5. The development of the metabolic syndrome and insulin resistance after adjuvant treatment for breast cancer.
Guinan EM; Connolly EM; Healy LA; Carroll PA; Kennedy MJ; Hussey J
Cancer Nurs; 2014; 37(5):355-62. PubMed ID: 24088604
[TBL] [Abstract][Full Text] [Related]
6. Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer.
Gupta S; Singh M; Vora A; Babu G; Walia M; Nautial V; Saha R; Smruti BK; Sharma JB; Koul R; Parikh PM; Aggarwal S
South Asian J Cancer; 2018; 7(2):142-145. PubMed ID: 29721482
[TBL] [Abstract][Full Text] [Related]
7. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
8. Key metabolic parameters change significantly in early breast cancer survivors: an explorative PILOT study.
Fredslund SO; Gravholt CH; Laursen BE; Jensen AB
J Transl Med; 2019 Apr; 17(1):105. PubMed ID: 30935397
[TBL] [Abstract][Full Text] [Related]
9. Risk of cardiac disease after adjuvant radiation therapy among breast cancer survivors.
Chang JS; Shin J; Park EC; Kim YB
Breast; 2019 Feb; 43():48-54. PubMed ID: 30447482
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome in breast cancer survivors with high carbohydrate consumption: The first report in community setting.
Park B; Kong SY; Lee EK; Lee MH; Lee ES
Clin Nutr; 2017 Oct; 36(5):1372-1377. PubMed ID: 27686692
[TBL] [Abstract][Full Text] [Related]
11. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors.
Ganz PA; Rowland JH; Meyerowitz BE; Desmond KA
Recent Results Cancer Res; 1998; 152():396-411. PubMed ID: 9928575
[TBL] [Abstract][Full Text] [Related]
12. Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.
Wells KJ; Pan TM; Vázquez-Otero C; Ung D; Ustjanauskas AE; Muñoz D; Laronga C; Roetzheim RG; Goldenstein M; Carrizosa C; Nuhaily S; Johnson K; Norton M; Sims E; Quinn GP
Support Care Cancer; 2016 Oct; 24(10):4123-30. PubMed ID: 27146492
[TBL] [Abstract][Full Text] [Related]
13. Skeletal health in breast cancer survivors.
Bruyère O; Bergmann P; Cavalier E; Gielen E; Goemaere S; Kaufman JM; Rozenberg S; Body JJ
Maturitas; 2017 Nov; 105():78-82. PubMed ID: 28838807
[TBL] [Abstract][Full Text] [Related]
14. Is Gonadal Therapy a Promoter of Breast Cancer? Incidence of Breast Cancer in a Cohort of Survivors of Oncological Diseases Treated with Gonadal Steroids.
Dias D; Esteves S; Andrade S; Maciel J; Cavaco D; Simões-Pereira J; Pereira MC
Case Rep Oncol; 2020; 13(1):347-357. PubMed ID: 32308603
[TBL] [Abstract][Full Text] [Related]
15. Cognitive Deficits in Breast Cancer Survivors After Chemotherapy and Hormonal Therapy.
Frank JS; Vance DE; Triebel KL; Meneses KM
J Neurosci Nurs; 2015 Dec; 47(6):302-12. PubMed ID: 26447567
[TBL] [Abstract][Full Text] [Related]
16. Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature Review.
Hurtado-de-Mendoza A; Cabling ML; Lobo T; Dash C; Sheppard VB
Clin Breast Cancer; 2016 Aug; 16(4):247-255.e3. PubMed ID: 27133733
[TBL] [Abstract][Full Text] [Related]
17. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study.
van der Willik KD; Koppelmans V; Hauptmann M; Compter A; Ikram MA; Schagen SB
Breast Cancer Res; 2018 Nov; 20(1):135. PubMed ID: 30442190
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
[TBL] [Abstract][Full Text] [Related]
19. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
[TBL] [Abstract][Full Text] [Related]
20. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
Ward JH
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
